# Reinhard Vogt

> Reinhard Vogt is a seed investor at Dynamk Capital (New York) backing Health Care and Life Science. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Dynamk Capital](https://shizune.co/investors/profile/dynamk-capital)
- Location: New York, United States
- Total investments: 2
- Last investment: Apr 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/reinhard-vogt-46babb182
- Website: http://www.dynamk.vc

Reinhard Vogt is a seed investor at Dynamk Capital in New York focused on Health Care and Life Science. Reinhard Vogt is the Managing Director at Dynamk Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Norway | 1 | 50% |
| Switzerland | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bionter | Bionter operates as a company with the purpose of revolutionizing analytical testing for the benefit of people's health. | $3M | Seed | Apr 27, 2022 |  |
| Vectron Biosolutions | Vectron Biosolutions is develops and markets vector technologies to biotechnology and life science industries. The company offers bacterial cloning vectors; expression vectors engineered for recombinant protein production in bacteria; customize vectors for specific applications; and recombinant proteins. It also provides protein production, vectordesign, and molecular engineering services to help its clients in life science research activities. | $2.7M | Series A | Jun 17, 2021 |  |

2 of 2 investments shown.

## About Dynamk Capital

VC Fund · New York, United States

Dynamk Capital invests in innovative tools and technologies that are critical for the discovery, development and production of life-saving therapies.We partner with life science visionaries whose market-defining ideas are shaping the future of how therapeutics are being developed, increasing access for patients, and reducing costs.

4 contacts available at Dynamk Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Daniella Kranjac | Founding Partner | https://shizune.co/investors/profile/daniella-kranjac |
| Reinhard Vogt | Managing Director | https://shizune.co/investors/profile/reinhard-vogt |
| Gustavo Mahler | Venture Partner | https://shizune.co/investors/profile/gustavo-mahler |
| Sebastien Latapie | Principal | https://shizune.co/investors/profile/sebastien-latapie |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Reinhard Vogt invest in?

Reinhard Vogt invests primarily in Health Care, Life Science and Biotechnology startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Reinhard Vogt last invest?

The most recent investment recorded for Reinhard Vogt closed in Apr 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co